Compass Therapeutics, Inc.
CMPXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Compass Therapeutics, Inc. (CMPX) is listed under Biotechnology. The company carries a $428.6M market cap, placing it firmly in the small-cap category. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Market Cap
$428.6M
Beta
0.84
P/E (TTM)
—
P/E (Fwd)
-4.45
EPS (TTM)
$-0.39
EPS (Fwd)
$-0.54
ROE
-56.7%
ROA
-33.0%
Cash
$179.9M
Total Debt
$9.6M
Free CF
-$31.4M
52W Change
-31.6%
Annual Financials
Cash vs Debt
Where CMPX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CMPX finished 31.55% below its 150-day moving average ($3.55) and 39.25% below its 200-day moving average ($4.00). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CMPX overbought or oversold?
At the September 3, 2026 close, CMPX's RSI(14) was 58.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Compass Therapeutics, Inc. holds $179.9M in cash against $9.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$31.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -56.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Compass Therapeutics, Inc.'s trajectory.